OMT-28
/ OMEICOS
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
October 13, 2025
OMT-28, a synthetic analog of 17,18-epoxyeicosatetraenoic acid, mitigates lipopolysaccharide-induced lung injury in mice.
(PubMed, Eur J Pharmacol)
- "SIRT3 silencing abolished the anti-inflammatory and epithelial cell integrity effects of OMT-28 in BEAS-2B cells and A549 cells. Overall, these findings indicate that OMT-28 may protect against LPS-induced lung injury by maintaining SIRT3 expression and mitochondrial function."
Journal • Preclinical • Acute Respiratory Distress Syndrome • Inflammation • Metabolic Disorders • Pneumonia • Pulmonary Disease • Respiratory Diseases • CCL2 • CXCL8 • IL1B • IL6 • SIRT3 • TJP1 • TNFA
August 23, 2024
OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION)
(clinicaltrials.gov)
- P2 | N=32 | Active, not recruiting | Sponsor: Omeicos Therapeutics GmbH | Recruiting ➔ Active, not recruiting
Enrollment closed • Cardiomyopathy • Cardiovascular • Inflammation • Metabolic Disorders • Myositis • GDF15
May 17, 2024
Cardioprotective properties of OMT-28, a synthetic analog of omega-3 epoxyeicosanoids.
(PubMed, J Biol Chem)
- "Furthermore, OMT-28 (1 μM) limited IR-induced NLRP3 inflammasome activation similarly like a direct NLRP3 inhibitor (MCC950). Overall, this study demonstrates that OMT-28 possesses potent cardio-protective and anti-inflammatory properties supporting the hypothesis that extending the bioavailability of omega-3 epoxyeicosanoids may improve their prospects as therapeutic agents."
Journal • Cardiovascular • Reperfusion Injury • NLRP3 • PPARA • SIRT1 • TNFA
January 11, 2024
OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION)
(clinicaltrials.gov)
- P2 | N=32 | Recruiting | Sponsor: Omeicos Therapeutics GmbH | Phase classification: P2a ➔ P2
Phase classification • Cardiomyopathy • Cardiovascular • Inflammation • Metabolic Disorders • Myositis • GDF15
September 06, 2023
OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION)
(clinicaltrials.gov)
- P2a | N=32 | Recruiting | Sponsor: Omeicos Therapeutics GmbH | Trial completion date: Sep 2024 ➔ Jun 2025 | Trial primary completion date: Jul 2024 ➔ Mar 2025
Trial completion date • Trial primary completion date • Cardiomyopathy • Cardiovascular • Inflammation • Metabolic Disorders • Myositis • GDF15
September 01, 2023
OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION)
(clinicaltrials.gov)
- P2a | N=32 | Recruiting | Sponsor: Omeicos Therapeutics GmbH | N=16 ➔ 32
Enrollment change • Cardiomyopathy • Cardiovascular • Inflammation • Metabolic Disorders • Myositis • GDF15
August 02, 2023
OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION)
(clinicaltrials.gov)
- P2a | N=16 | Recruiting | Sponsor: Omeicos Therapeutics GmbH
New P2a trial • Cardiomyopathy • Cardiovascular • Inflammation • Metabolic Disorders • Myositis • GDF15
March 28, 2023
A clinical study of a new drug (OMT-28) for use in patients suffering from the genetic disease PMD including muscle disease and/or Heart muscle disease and inflammation (PMD-OPTION) Eine klinische Studie mit einem neuen Medikament (OMT-28) zurAnwendung bei Patienten, die unter der genetischen Erkrankung PMDleiden, zusammen mit Muskelerkrankung und/oder Herzmuskelerkrankungund Entzündung...
(clinicaltrialsregister.eu)
- P2 | N=22 | Ongoing | Sponsor: OMEICOS Therapeutics GmbH
New P2 trial • Cardiomyopathy • Cardiovascular • Genetic Disorders • Inflammation • Metabolic Disorders • Myositis • GDF15
September 09, 2021
PROMISE-AF: Study on OMT-28 in Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation (AF)
(clinicaltrials.gov)
- P2; N=136; Completed; Sponsor: Omeicos Therapeutics GmbH; Recruiting ➔ Completed
Clinical • Trial completion • Atrial Fibrillation • Cardiovascular
July 21, 2020
Assessment of OMT-28, a synthetic analog of omega-3 epoxyeicosanoids, in patients with persistent atrial fibrillation: Rationale and design of the PROMISE-AF phase II study.
(PubMed, Int J Cardiol Heart Vasc)
- P2 | "The primary efficacy analysis will be conducted on the modified intention-to-treat (mITT) population, whereas the safety analysis will be done on the safety population. Although ICMs have been used in other interventional studies to assess arrhythmia, PROMISE-AF will be the first study to assess antiarrhythmic efficacy and safety of a novel rhythm-stabilizing drug after DCC by using ICMs."
Clinical • Journal • P2 data • Atrial Fibrillation • Cardiovascular
1 to 10
Of
10
Go to page
1